HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lane, M.-A. Articles by Blair, P. B. Search for Related Content PubMed Articles by Lane, M.-A. Articles by Blair, P. B.

Characterization of Cytotoxic Effector Cells in the Mouse Mammary Tumor System¹

Department of Bacteriology and Immunology and the Cancer Research Laboratory, University of California, Berkeley, California 94720

Abstract

Cell types involved in the immune response in vitro to MTV-induced BALB/cfC3H mammary tumors have been studied with techniques designed to inactivate or deplete different cytotoxic effector cells from spleen cell populations. The minimal activity of spleen cells from neonatally MTV-infected virgin BALB/cfC3H females is dependent upon the presence of T cells. Spleens from multiparous BALB/cfC3H females have a more active T cell population, and, in addition, a non-T cell population which is active early in the culture period. Responses of spleen cells from multiparous BALB/cfC3H females bearing small tumors are similar to those of tumor-free multiparous females. However, after the tumors grow to large size, the activity of the non-T cell population is no longer detectable. The cytotoxic activity of spleen cells from BALB/c females older than 14 weeks (supposedly not infected with MTV) is not dependent upon the presence of T cells. No activity is shown by spleen cells from BALB/c females younger than 14 weeks. Positive control spleen cells were obtained from C3H female mice who had been immunized to BALB/c histocompatibility antigens by a skin allograft; both a T cell and a non-T cell response were found.

Footnotes

¹ This research was supported by National Institutes of Health Research Grants CA 05388, AI-120-10, AI-8817-06, and FO3-CA-52402-02.

² Address after September 1, 1974: Department of Neurobiology and Behavior, Cornell University, Ithaca, New York.

³ Address after July 1, 1974: Clinical Immunology, Rheumatology Section, Veterans Administration Hospital, San Francisco, California 94121.

⁴ Present address: Department of Biology, University of California at San Diego, La Jolla, California 92037.

⁵ Requests for reprints should be addressed to Dr. Phyllis B. Blair, Department of Bacteriology and Immunology, University of California, Berkeley, California 94720.